Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Withdrawn

Conditions: Metastatic Breast Cancer
Stage IV Breast Cancer
Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Capecitabine
Drug: Motesanib

First Posted Date: 2011-05-06

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT01349088

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: TheraSphere

First Posted Date: 2011-05-06

Last Posted Date: 2021-09-01

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 474

Registration Number: NCT01349075

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

Phase 2

Completed

Conditions: Hematological Malignancies

Interventions: Radiation: Total Body Irradiation
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Drug: Fludarabine
Drug: Busulfan
Genetic: Hematopoietic stem cell transplantation

First Posted Date: 2011-05-06

Last Posted Date: 2022-12-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 80

Registration Number: NCT01349101

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Robotic Seed Implantation for Prostate Cancer Brachytherapy

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Device: EUCLIDIAN Robot

First Posted Date: 2011-04-25

Last Posted Date: 2017-04-12

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 2

Registration Number: NCT01341288

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Phase 2

Completed

Conditions: Hematologic Malignancy

Interventions: Radiation: Total Body Irradiation
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Procedure: Allogeneic hematopoietic stem cell transplantation
Other: Laboratory biomarker analysis

First Posted Date: 2011-04-25

Last Posted Date: 2018-04-25

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 25

Registration Number: NCT01341301

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer

Not Applicable

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: Temsirolimus
Drug: Cetuximab
Drug: Cisplatin
Device: Radiation Therapy

First Posted Date: 2011-03-30

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT01326468

Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Phase 1

Terminated

Conditions: High-grade Meningioma
Brain Metastasis
Recurrent Glioma

Interventions: Drug: Panobinostat
Radiation: Stereotactic body radiation therapy
Procedure: Quality-of-life assessment
Radiation: Stereotactic radiosurgery

First Posted Date: 2011-03-29

Last Posted Date: 2016-12-09

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 17

Registration Number: NCT01324635

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Leukemia
Multiple Myeloma
Hodgkin's Disease
Lymphoma
Hematological Malignancies

Interventions: Device: Matched Sibling Allogeneic Transplantation

First Posted Date: 2011-03-15

Last Posted Date: 2019-10-15

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 47

Registration Number: NCT01315132

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Phase 2

Terminated

Conditions: Castrate Resistant Prostate Cancer
Prostate Cancer
Chemotherapy Naive Prostate Cancer

Interventions: Drug: Pasireotide
Drug: Everolimus
Other: Laboratory biomarker analysis

First Posted Date: 2011-03-11

Last Posted Date: 2018-04-25

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 6

Registration Number: NCT01313559

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Early Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Mantle Cell Lymphoma
Adult T-cell Leukemia/Lymphoma
Burkitt Lymphoma
Lymphoid Malignancies (New or Relapsed)
Lymphoblastic Lymphoma

Interventions: Drug: Hyper-CVAD
Drug: Sirolimus

First Posted Date: 2010-08-19

Last Posted Date: 2017-12-18

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 7

Registration Number: NCT01184885

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy